1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Synergy Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Synergy Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 28 pages

Synergy Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Synergy Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Synergy Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Synergy Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Synergy Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Synergy Pharmaceuticals, Inc. - Brief Synergy Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Synergy Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Synergy Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Synergy Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Synergy Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Synergy Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Synergy Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Synergy Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Synergy Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Synergy Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Synergy Pharmaceuticals, Inc. Snapshot 4
Synergy Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Synergy Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Synergy Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Synergy Pharmaceuticals, Inc. - Pipeline Products Glance 9
Synergy Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Synergy Pharmaceuticals, Inc. - Drug Profiles 10
FV-100 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
plecanatide 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
SP-333 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Synergy Pharmaceuticals, Inc. - Pipeline Analysis 13
Synergy Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 13
Synergy Pharmaceuticals, Inc. - Pipeline Products By Target 14
Synergy Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 15
Synergy Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 16
Synergy Pharmaceuticals, Inc. - Recent Pipeline Updates 17
Synergy Pharmaceuticals, Inc. - Dormant Projects 24
Synergy Pharmaceuticals, Inc. - Discontinued Pipeline Products 25
Discontinued Pipeline Product Profiles 25
degrasyns Program 25
Synergy Pharmaceuticals, Inc. - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28



List of Tables

Synergy Pharmaceuticals, Inc., Key Information 4
Synergy Pharmaceuticals, Inc., Key Facts 4
Synergy Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Synergy Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Synergy Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Synergy Pharmaceuticals, Inc. - Phase II, 2013 9
Synergy Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 13
Synergy Pharmaceuticals, Inc. - Pipeline By Target, 2013 14
Synergy Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 15
Synergy Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 16
Synergy Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 17
Synergy Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 24
Synergy Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013 25



List of Figures

Synergy Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Synergy Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Synergy Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Synergy Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 13



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.